Illumina, Inc. (NASDAQ: ILMN) announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, ...

"Population-scale spatial has arrived and is on center-stage at AGBT 2026," stated Christopher Mason, PhD, Professor of Physiology and Biophysics at Weill Cornell Medicine. " [Jiwoon Park] is ...

We combine advanced technologies such as spatial transcriptomics, multiplexed imaging, and in situ sequencing to map cellular components in their native tissue context. Obtain high-resolution data ...

Takara Bio USA collaborates with Illumina on a single-cell-resolution spatial mapping workflow, presented at AGBT 2026.

"Spatial transcriptomics opens entirely new pathways to gain crucial insight into the cellular function of organisms," said Steve Barnard, PhD, chief technology officer of Illumina. "Illumina spatial ...

A new spatial transcriptomic technology captures RNA patterns without requiring expensive imaging ...

Left: Imaging of lamin A/C structures in a physically expanded nucleus from an individual with progeria. Right: Same, but with 3D genomic reads overlaid in their original spatial locations, colored by ...

Spatial transcriptomics is a technique that provides information about gene expression patterns within intact tissues. This technology employs various methodologies, including in situ sequencing (ISS) ...

Spatial ribonucleic acid (RNA) transcriptomics measures gene expression while preserving each molecule’s coordinates in intact tissue, tying transcripts to histology and local microenvironments.

Takara Bio USA, Inc. ("Takara Bio USA"), a wholly owned subsidiary of Takara Bio Inc. ("Takara Bio"), today announced a series of updates to its spatial biology product portfolio, extending its ...